ATXI Avenue Therapeutics Inc

USD 3.45 0.00 0
Icon

Avenue Therapeutics Inc (ATXI) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 3.45

0.00 (0.00)%

USD 3.29M

0.01M

N/A

USD 8.30 (+140.58%)

Icon

ATXI

Avenue Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 3.45
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 3.29M

USD 8.30 (+140.58%)

USD 3.45

Avenue Therapeutics Inc (ATXI) Stock Forecast

N/A

Based on the Avenue Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Avenue Therapeutics Inc is not available over the next 12 months. Avenue Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Avenue Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Avenue Therapeutics Inc’s stock price was USD 3.45. Avenue Therapeutics Inc’s stock price has changed by -1.15% over the past week, +2.68% over the past month and -95.96% over the last year.

No recent analyst target price found for Avenue Therapeutics Inc
No recent average analyst rating found for Avenue Therapeutics Inc

Company Overview Avenue Therapeutics Inc

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bu...Read More

https://www.avenuetx.com

1111 Kane Concourse, Tampa, FL, United States, 33154

3

December

USD

USA

Adjusted Closing Price for Avenue Therapeutics Inc (ATXI)

Loading...

Unadjusted Closing Price for Avenue Therapeutics Inc (ATXI)

Loading...

Share Trading Volume for Avenue Therapeutics Inc Shares

Loading...

Compare Performance of Avenue Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ATXI

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Avenue Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +4.34 (+0.88%) USD126.85B 31.94 20.00

ETFs Containing ATXI

Symbol Name ATXI's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Avenue Therapeutics Inc (ATXI) Stock

Stock Target Advisor's fundamental analysis for Avenue Therapeutics Inc's stock is Bearish.

Unfortunately we do not have enough data on ATXI's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on ATXI's stock to indicate what its average analyst target is.

ATXI stock's Price/Earning ratio is 0.28. Our analysis grades ATXI stock's Price / Earning ratio at B-. This means that ATXI stock's Price/Earning ratio is above 20% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ATXI may be undervalued for its sector.

The last closing price of ATXI's stock was USD 3.45.

The most recent market capitalization for ATXI is USD 3.29M.

Unfortunately we do not have enough analyst data on ATXI's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Avenue Therapeutics Inc's stock.

As per our most recent records Avenue Therapeutics Inc has 3 Employees.

Avenue Therapeutics Inc's registered address is 1111 Kane Concourse, Tampa, FL, United States, 33154. You can get more information about it from Avenue Therapeutics Inc's website at https://www.avenuetx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...